Peer Review, UGC Care
APPROACH FOR QUANTITATIVE ESTIMATION OF EPROSARTAN MESYLATE BY UV SPECTROPHOTOMETER
View PDF

Keywords

Eprosartan Mesylate, Beer’s Law, UV Spectrophotometry, Quantitative estimation.

How to Cite

Rewar S, Bansal , B., Singh , C., & Sharma , A. (2014). APPROACH FOR QUANTITATIVE ESTIMATION OF EPROSARTAN MESYLATE BY UV SPECTROPHOTOMETER. International Journal of Research and Development in Pharmacy & Life Sciences, 3(6), 1288-1291. Retrieved from https://ijrdpl.com/index.php/ijrdpl/article/view/406

Abstract

Eprosartan Mesylate is an angiotensin II receptor (AT1) antagonist. Eprosartan Mesylate is an effective, well tolerated and potent pure competitive antagonist of the AT1 receptor and hence there has been significant research on broad range of analytical and detection techniques that could be useful in its estimation in formulations and biological matrices. A simple, sensitive and accurate UV spectrometric method has been developed for the determination of eprosartan Mesylate in raw material and experimental tablets. Beer’s law was obeyed in the concentration range 2-3µgmL-1 for the drug (=233nm) with an apparent molar absorptivity and sandell sensitivity of 2.8×104Lmol-1cm-1 and0.01854µgcm-2/0.001A, respectively. The limit of detection and quantitation were calculated to be 0.3623 and 1.098 µg mL-1, respectively. Results were validated statistically according to ICH guidelines. Validation of the method yielded good result in the concerning range (2-30µg mL-1), linearity (r2 = 0.9998), precision and accuracy. The excipients present in the experimental tablet did not interfere with the method.

View PDF

References

Myers MG: Ambulatory blood pressure monitoring in the assessment of antihypertensive therapy. Blood Press Monit 1999; 4:185–188.

Coats AJS, Radaelli A, Clark SJ, Conway J, Sleight P: The influence of ambulatory blood pressure monitoring on the design and interpretation of trials in hypertension. J Hypertens 1992; 10:385–391.

Ruddy TD, Fodor JG: Nisoldipine CC and lisinopril alone or in combination for treatment of mild to moderate systemic hypertension: Canadian Nisoldipine CC Hypertension Trial Group. Cardiovasc Drugs Ther 1997; 11:581–590.

White WB, McCabe EJ, Mansoor GA: Comparison of office and ambulatory blood pressure measurements to assess the angiotensin II receptor antagonist eprosartan. Blood Press Monit 1996; 1:45–51.

McClellan KJ, Balfour JA: Eprosartan. Drugs 1998; 55:713–718.

Sica DA, Hollenberg N: The renal profile of eprosartan, a novel AT1-receptor antagonist. Pharmacotherapy 1999; 19:86S–94S.

Ohlstein EH, Brooks DP, Feuerstein GZ, Ruffolo RR Jr: Inhibition of sympathetic outflow by the angiotensin II receptor antagonist eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade. Pharmacology 1997; 55:244–251.

The Merck Index, 14th edition, Merck Research Laboratories, (Monograph #3635), 621(2006).

Kamila MM, Mondal N, Ghosh LK (2008) Spectrophotometric Determination of Eprosartan Mesylate in Raw Material and Experimental Tablets. Indian Journal of Chemical Technology 15: 194-196.

Kumar P, Ramulu S (2010) Stability Indicating RP-HPLC Method for Determination of Eprosartan in Pure and Pharmaceutical Formulation. International Journal of Pharmaceutical Sciences Review and Research 4: 54- 59.

Hemke AT, Bhure MV, Chouhan KS, Gupta KR, Wadodkar SG (2010) UV spectrophotometric determination of hydrochlorthiazide and olmesartan medoxomil in pharmaceutical formulation. European Journal of Chemistry 7: 1156-1161.

Ferreiros N, Iriarte G, Alonso RM, Jimenez RM and Ortiz E, J.Chromatogr. A, 1119(1 – 2), 2006, 309 – 314.

Gupta Y, Shrivastava A, Duggal D, Patel A, Agrawal S (2009) A new RPHPLC method for simultaneous estimation of nebivolol hydrochloride and hydrochlorthiazide in dosage forms. Pharmaceutical Analysis 1: 264-269.

M. T. Raju, S. Gurrala, Developmet and Validation of HPLC-UV Method for the Estimation of Eprosartan in Human Plasma, Int. J. Pharmaceut. Pharmaceut. Sci., 3(2), 58-61 (2011).

ICH guidelines Q2A. Text on validation of analytical procedures: Methodology. In the proceedings of International Conference on Harmonization, Geneva, March 1994, pp 1 – 5.

ICH guidelines Q2B. Text on Validation of analytical procedures: Methodology in the proceedings of International Conference on Harmonization, Geneva, March, 1996, pp. 1 – 8.

Hillaert S and Van den Bossche, J. Pharm.Biomed.Anal., 31, 2003, 329 – 339.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

Copyright (c) 2020 Array

Downloads

Download data is not yet available.